Follow-up bone mineral density testing: 2023 official positions of the International Society for Clinical Densitometry

IF 1.7 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Journal of Clinical Densitometry Pub Date : 2023-11-02 DOI:10.1016/j.jocd.2023.101440

Linsey U. Gani , Chanika Sritara , Robert D. Blank , WeiWen Chen , Julia Gilmour , Ruban Dhaliwal , Ranjodh Gill

{"title":"Follow-up bone mineral density testing: 2023 official positions of the International Society for Clinical Densitometry","authors":"Linsey U. Gani , Chanika Sritara , Robert D. Blank , WeiWen Chen , Julia Gilmour , Ruban Dhaliwal , Ranjodh Gill","doi":"10.1016/j.jocd.2023.101440","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Dual-energy X-ray absorptiometry (DXA) is the gold standard method for measuring bone mineral density (BMD) which is most strongly associated with fracture risk. BMD is therefore the basis for the World Health Organization's densitometric definition of osteoporosis. The International Society for Clinical </span>Densitometry (ISCD) promotes best densitometry practices and its official positions reflect critical review of current evidence by domain experts. This document reports new official positions regarding follow-up DXA examinations based on a </span>systematic review<span> of literature published through December 2022. Adoption of official positions requires consensus agreement from an expert panel following a modified RAND protocol. Unless explicitly altered by the new position statements, prior ISCD official positions remain in force. This update reflects increased consideration of the clinical context prompting repeat examination. Follow-up DXA should be performed with pre-defined objectives when the results would have an impact on patient management. Testing intervals should be individualized according to the patient's age, sex, fracture risk and treatment history. Incident fractures and therapeutic approach are key considerations. Appropriately ordered and interpreted follow-up DXA examinations support diagnostic and therapeutic decision making, thereby contributing to excellent clinical care. Future research should address the complementary roles of clinical findings, imaging and laboratory testing to guide management.</span></p></div>","PeriodicalId":50240,"journal":{"name":"Journal of Clinical Densitometry","volume":"27 1","pages":"Article 101440"},"PeriodicalIF":1.7000,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Densitometry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094695023000902","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Dual-energy X-ray absorptiometry (DXA) is the gold standard method for measuring bone mineral density (BMD) which is most strongly associated with fracture risk. BMD is therefore the basis for the World Health Organization's densitometric definition of osteoporosis. The International Society for Clinical Densitometry (ISCD) promotes best densitometry practices and its official positions reflect critical review of current evidence by domain experts. This document reports new official positions regarding follow-up DXA examinations based on a systematic review of literature published through December 2022. Adoption of official positions requires consensus agreement from an expert panel following a modified RAND protocol. Unless explicitly altered by the new position statements, prior ISCD official positions remain in force. This update reflects increased consideration of the clinical context prompting repeat examination. Follow-up DXA should be performed with pre-defined objectives when the results would have an impact on patient management. Testing intervals should be individualized according to the patient's age, sex, fracture risk and treatment history. Incident fractures and therapeutic approach are key considerations. Appropriately ordered and interpreted follow-up DXA examinations support diagnostic and therapeutic decision making, thereby contributing to excellent clinical care. Future research should address the complementary roles of clinical findings, imaging and laboratory testing to guide management.

查看原文本刊更多论文

随访骨密度测试:2023年国际临床密度测量学会官方职位

双能x线骨密度测定法(DXA)是测量骨密度(BMD)的金标准方法，骨密度与骨折风险密切相关。因此，骨密度是世界卫生组织骨质疏松症的密度定义的基础。国际临床密度测量学会(ISCD)促进最佳密度测量实践，其官方立场反映了领域专家对当前证据的批判性审查。本文件基于对截至2022年12月发表的文献的系统回顾，报告了关于后续DXA检查的新官方立场。官方立场的采纳需要专家小组按照修改后的兰德协议达成一致意见。除非新的立场声明明确改变，否则先前的ISCD官方立场仍然有效。这一更新反映了对促使重复检查的临床背景的更多考虑。当结果对患者管理有影响时，应按照预先设定的目标进行随访DXA。检测间隔应根据患者的年龄、性别、骨折风险和治疗史进行个体化。偶发性骨折和治疗方法是关键考虑因素。适当安排和解释的后续DXA检查支持诊断和治疗决策，从而有助于优秀的临床护理。未来的研究应解决临床表现，影像学和实验室检测的互补作用，以指导管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Densitometry 医学-内分泌学与代谢

CiteScore

4.90

自引率

8.00%

发文量

审稿时长

90 days

期刊介绍： The Journal is committed to serving ISCD''s mission - the education of heterogenous physician specialties and technologists who are involved in the clinical assessment of skeletal health. The focus of JCD is bone mass measurement, including epidemiology of bone mass, how drugs and diseases alter bone mass, new techniques and quality assurance in bone mass imaging technologies, and bone mass health/economics. Combining high quality research and review articles with sound, practice-oriented advice, JCD meets the diverse diagnostic and management needs of radiologists, endocrinologists, nephrologists, rheumatologists, gynecologists, family physicians, internists, and technologists whose patients require diagnostic clinical densitometry for therapeutic management.